 AIM ImmunoTech Inc NYSE: AIM has submitted a Pre-Investigational New Drug application Pre-IND to the FDA for a Phase 2 study of Ampligen as a potential infusion therapy for Post-COVID-19 Cognitive Dysfunction PCCD. The trial will evaluate the efficacy and safety of Ampligen in patients experiencing PCCD. 